ProMIS Neurosciences (PMN) Investor presentation summary

Profile and market opportunity

• EpiSelect computational platform predicts misfolded proteins and exposed epitopes; pipeline of antibodies and vaccines targets disease-causing misfolded proteins.

• Alzheimer's affects 7.4M Americans today; prevalence among Americans 65+ is projected to reach 13.8M by 2060, with U.S. care costs of $409B in 2026.

• An estimated 95% of 1.26M early-stage, label-eligible U.S. patients remain untreated; ~63K are treated, despite ~$1.4B in annualized global sales for approved anti-amyloid therapies.

• Current therapies face ARIA risks, infusion and MRI access requirements, contraindications, and estimated $5–7K annual out-of-pocket costs for some Medicare patients.

PMN310 mechanism and early evidence

• PMN310 is designed to bind toxic Aβ oligomers while avoiding abundant monomers and plaque; IgG1 effector function may recruit microglia to clear bound oligomers.

• In Phase 1a, 40 healthy volunteers received one of five doses; PMN310 was generally well tolerated, had an ~27-day CSF half-life, and reached CSF levels 100–600x the estimated target concentration.

• Exploratory Phase 1a SFIDA results showed fewer detectable CSF oligomer particles versus placebo at 5–40 mg/kg on Days 3 and 29, across particle sizes.

• In PRECISE-AD, the 6-month blinded interim showed 0% ARIA-E, 4.4% total ARIA (all mild, asymptomatic ARIA-H), no treatment-related serious adverse events, and no treatment-related discontinuations.

PRECISE-AD interim results

• Phase 1b is a 12-month, randomized, double-blind, placebo-controlled monthly IV study; 144 patients enrolled across 22 sites, with 136 safety-evaluable at the interim cutoff.

• Enrollment included 61% APOE4 carriers and 11% ε4/ε4 homozygotes, the group at highest ARIA risk with current anti-amyloid therapies.

• In pooled, blinded 3:1 drug-plus-placebo data, plasma pTau217 declined 15% by Day 169; 68.5% of patients had a decline.

• Pooled, blinded CSF MTBR-tau243 declined 13.3% by Day 169; 62.5% of patients had a decline. The interim biomarker analysis was not powered for significance.